<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931073</url>
  </required_header>
  <id_info>
    <org_study_id>B1451017</org_study_id>
    <nct_id>NCT00931073</nct_id>
  </id_info>
  <brief_title>A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers</brief_title>
  <official_title>A Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the potential for a drug-drug interaction of Dimebon with
      ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and
      CYP2C19, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dimebon alone: Dimebon PK in CYP2D6 EMs and PMs (Cmax, Tmax, AUCinf (as data permit), AUClast, and t1/2 (as data permit), CL/F (as data permit) and V/F (as data permit))</measure>
    <time_frame>Period 1 Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dimebon + keto: Dimebon PK in CYP2D6 EMs and PMs (Cmax, Tmax, AUCinf (as data permit), AUClast, and t1/2 (as data permit), CL/F (as data permit) and V/F (as data permit))</measure>
    <time_frame>Period 2 Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dimebon + omeprazole: Dimebon PK in CYP2D6 EMs and PMs (Cmax, Tmax, AUCinf (as data permit), AUClast, and t1/2 (as data permit), CL/F (as data permit) and V/F (as data permit))</measure>
    <time_frame>Period 3 Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dimebon alone: Safety and tolerability (AE's, ECG, vital signs, safety labs)</measure>
    <time_frame>Period 1 Day 1-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dimebon + keto: Safety and tolerability (AE's, ECG, vital signs, safety labs)</measure>
    <time_frame>Period 2 Day 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dimebon + omeprazole: Safety and tolerability (AE's, ECG, vital signs, safety labs)</measure>
    <time_frame>Period 3 Day 1-13</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimebon alone</intervention_name>
    <description>Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening</description>
    <arm_group_label>Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimebon + Ketoconazole</intervention_name>
    <description>Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening</description>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimebon + Omeprazole</intervention_name>
    <description>Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening</description>
    <arm_group_label>Period 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

          -  Subjects must have either a CYP2D6 EM (n=12) or PM (n=12) status based on genotyping
             at screening.

          -  Subjects must have a CYP2C19 EM status based on status at screening.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease.

          -  Subjects with any history of a previous seizure or convulsion or significant head
             trauma.

          -  Subjects specifically allergic to imidazole antifungal agents.

          -  Subjects specifically allergic to omeprazole or other proton pump inhibitors.

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  Subjects with hypersensitivity reactions to Dimebon or other antihistamines.

          -  Consumption of grapefruit or grapefruit containing products within 7 days prior to the
             first dose of study medication.

          -  Subjects currently taking omeprazole, other proton pump inhibitors, antacids,
             H2-blockers or CYP2C19 inhibitors.

          -  Pregnant or nursing females; females of childbearing potential who are unwilling or
             unable to use an acceptable method of nonhormonal contraception as outlined in this
             protocol from at least 14 days prior to the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1451017&amp;StudyName=A%20Phase%20I%20Study%20To%20Estimate%20The%20Effect%20Of%20Ketoconazole%20And%20Omeprazole%20On%20The%20Pharmacokinetics%20Of%20Dimebon%20In%20Healthy%20Subjects%20Who%20Are</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>November 17, 2009</last_update_submitted>
  <last_update_submitted_qc>November 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Drug Interactions</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>CYP2C19</keyword>
  <keyword>ketoconazole</keyword>
  <keyword>omeprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

